Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Neutrophil extracellular trap formation (NETosis) has emerged as a pivotal regulator of the tumor immune microenvironment and a key determinant of response to cancer immunotherapy. NETs—web-like chromatin fibers decorated with histones, citrullinated histone H3, myeloperoxidase, neutrophil elastase, and matrix metalloproteinase-9—are induced by tumor-derived signals through classical lytic, vital non-lytic, and gasdermin D-dependent pathways, and exert context-dependent, predominantly pro-tumorigenic effects. Within the tumor microenvironment, NETs remodel the stroma, suppress CD8+ T-cell, natural killer-cell, and dendritic-cell function, promote regulatory T-cell and M2 macrophage polarization, and physically shield tumor cells from cytotoxic attack. By carrying programmed death-ligand 1 and driving T-cell exhaustion and immune exclusion, NETs compromise the efficacy of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1, CTLA-4, and next-generation checkpoints, as well as adoptive cell therapies. This review synthesizes the molecular mechanisms of NETosis, its multifaceted immunomodulatory roles, and emerging NET-derived biomarkers—including MPO-DNA and citrullinated histone H3-DNA complexes—that may predict immunotherapy response and toxicity. We further appraise therapeutic strategies, including PAD4 inhibitors, DNase I, CXCR2 antagonists, and nanoparticle-based platforms, and underscore the need for standardized NET quantification, careful preservation of host defense, and biomarker-guided clinical trials to translate NET modulation into durable improvements in immunotherapy outcomes.